Article

New antibiotics to draw interest for ophthalmologists

With the recent FDA approvals of fourth-generation fluoroquinolones,ophthalmologists now have two new antibiotics to fight bacteria in the eye.Moxifloxacin (Vigamox, Alcon), approved April 16, and gatifloxacin (Zymar,Allergan), approved March 31, are the latest therapies for the treatmentof bacterial conjunctivitis caused by susceptible strains of bacteria.At this year's ARVO meeting, ophthalmologists can gain knowledge andclinical information about the fourth-generation fluoroquinolones throughthe various clinical studies that will presented. In a session entitled"New Antibiotics," seven papers will focus exclusively on theclinical studies associated with these two drugs (Program #2114-#2120).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.